Therapeutics

Tools

Back to the Top
Search By Attributes

Search Results

Name Synonyms FDA Status Company Target Type Therapy Type Approved
For
ACU193 ACU-193 Alzheimer's Disease (Phase 1) Acumen Pharmaceuticals, Inc. Amyloid-Related Immunotherapy (passive)
AL044 Alzheimer's Disease (Phase 1) Alector Inflammation Immunotherapy (passive)
AL101 GSK-4527226 Alzheimer's Disease (Phase 1) Alector Other Immunotherapy (passive)
APNmAb005 RAA7 Alzheimer's Disease (Phase 1) Aprinoia Therapeutics Tau Immunotherapy (passive)
BMS-986446 PRX005 Alzheimer's Disease (Phase 1) Bristol-Myers Squibb, Prothena Tau Immunotherapy (passive)
IBC-Ab002 Alzheimer's Disease (Phase 1) ImmunoBrain Checkpoint Amyloid-Related, Inflammation, Other Immunotherapy (passive)
Lu AF87908 hC10.2 Alzheimer's Disease (Phase 1) Lundbeck Tau Immunotherapy (passive)
MEDI1814 Alzheimer's Disease (Phase 1) AstraZeneca, Eli Lilly & Co. Amyloid-Related Immunotherapy (passive)
MK-2214 Alzheimer's Disease (Phase 1) Merck Tau Immunotherapy (passive)
PNT001 Alzheimer's Disease (Phase 1), Traumatic Brain Injury (Phase 1) Pinteon Therapeutics Tau Immunotherapy (passive)
PRX012 Alzheimer's Disease (Phase 1) Prothena Amyloid-Related Immunotherapy (passive)
TB006 Alzheimer's Disease (Phase 1) TrueBinding, Inc. Inflammation Immunotherapy (passive)
Trontinemab RO7126209,
RG6102 ,
Brain shuttle gantenerumab
Alzheimer's Disease (Phase 1) Hoffmann-La Roche Amyloid-Related Immunotherapy (passive)